It is nearly eight years since healthcare and biotech investor Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Biotech valuations are lower relative to other sectors after a decade of stagnation. Denali Therapeutics fell 75% over five years despite its patented blood-brain barrier transport platform. Xenon ...

Plus: read our predictions for the five hottest AI trends to watch This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After a failed clinical trial in ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

An announcement from Anbio Biotechnology Class A ( (NNNN)) is now available. On December 30, 2025, Anbio Biotechnology reported unaudited financial results for the six months ended June 30, 2025, ...